The Somerville-based company, which uses its proprietary AI system in drug engineering and development, is seeking to go ...

By Arasu Kannagi Basil Feb 23 (Reuters) - Drug developer Generate Biomedicines said on Monday it was targeting a valuation of ...

Whisper it, but we may finally be seeing the IPO window reopening in 2026. | Whisper it, but we may finally be seeing the IPO window reopening in 2026.

Generate Biomedicines, a Massachusetts-based biotech leveraging an AI-powered discovery platform to "program biology" for breakthrough therapeutics, filed Monday with U.S. regulators to raise ...

Generate:Biomedicines plans to raise around $400 million in its initial public offering — a sum that hasn’t been seen for ...

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end ...

EIR Biopharma is hoping to bring in $17.1 million from an IPO on the New York Stock Exchange that could fund development of its preclinical eye disease drug. | EIR Biopharma is hoping to bring in $17.

Over the past two calendar years, acquirers have agreed to pay more than $38 billion to purchase venture-backed companies in ...

Biotech IPOs fell to a decade low in 2025 Investors expect more listings amid easing rate pressure Policy clarity under Trump has reduced worst-case fears Late-stage drug pipelines drawing renewed ...

Forgent, Eikon, and Bob’s Discount Furniture are making their debut in a mixed market for IPOs. SpaceX and other AI stocks are the bigger prize.

Generate Biomedicines Inc., a biotechnology firm using artificial intelligence in drug development, is seeking to raise as much as $425 million in an initial public offering, as listing activity in ...